Floatz logo

Tucatinib

Metastatic Neoplasm

QuantumLeap Healthcare CollaborativeSmall moleculePhase 2Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

144 Active assets in the Metastatic Neoplasm cohort.

Asset / SponsorPhaseRating
Fluorouracilum
Ruijin Hospital
Phase 4BBB
Xaliplatin
Ruijin Hospital
Phase 4BBB
Irinotecan
Eli Lilly and Company
Phase 4BBB
Dexasone
Janssen Research & Development, LLC
Phase 2BBB
Atezolizumab
UNC Lineberger Comprehensive Cancer Center
Phase 2/3BB

View all 49 →

Same molecule, other indications

Tucatinib is also rated in:

breast carcinomaActive
BB
Indicative · Phase 3
67 / 100
View asset →
invasive breast carcinomaActive
B
Indicative · Phase 3
63 / 100
View asset →
HER2 positive breast carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →